Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement-protected amphotropic retroviruses from murine packaging cells.

D Spitzer1, H Hauser, D Wirth

  • 1Department of Gene Regulation and Differentiation, GBF-National Research Center for Biotechnology, Braunschweig, Germany.

Human Gene Therapy
|August 14, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optical limiting properties of surface functionalized nanodiamonds probed by the Z-scan method.

Scientific reports·2019
Same author

A clickable NHC-Au(i)-complex for the preparation of stimulus-responsive metallopeptide amphiphiles.

Chemical communications (Cambridge, England)·2018
Same author

Folding induced supramolecular assembly into pH-responsive nanorods with a protein repellent shell.

Chemical communications (Cambridge, England)·2017
Same author

Optical properties of functionalized nanodiamonds.

Scientific reports·2017
Same author

First-Line Therapy for Patients With Multiple Myeloma: Direct and Indirect Comparison of Treatment Regimens on the Existing Market.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Costs and Effectiveness of Combination Therapy with Bedaquiline and other Anti-Tuberculosis Drugs in Patients with Multi- and Extensively Drug-Resistant Tuberculosis in Germany.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same journal

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026
Same journal

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration.

Human gene therapy·2026
Same journal

Hyperthermia-Enhanced Adeno-Associated Virus Gene Therapy: Mechanisms, Delivery Technologies, and Translational Potential.

Human gene therapy·2026
Same journal

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings.

Human gene therapy·2026
Same journal

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same journal

<i>In Vivo</i> Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1.

Human gene therapy·2026
See all related articles

Murine retroviruses are inactivated by human complement, hindering gene therapy. Researchers engineered a fusion protein, DAFF2A, to protect retroviruses from complement attack, creating a promising tool for in vivo gene therapy applications.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Immunology

Background:

  • Murine retroviruses are susceptible to inactivation by the human complement system, limiting their use in in vivo gene therapy.
  • The human complement system poses a significant barrier to the efficacy of retroviral vectors in clinical applications.

Purpose of the Study:

  • To engineer amphotropic retroviruses with enhanced resistance to human complement-mediated inactivation.
  • To develop a novel fusion protein for improved retroviral vector stability in vivo.

Main Methods:

  • Generated a fusion protein, DAFF2A, by combining the decay-accelerating factor (DAF) with the amphotropic murine leukemia virus (MuLV) 4070A envelope protein (EnvA).
  • Expressed the DAFF2A fusion protein in NIH 3T3 helper cells and confirmed its presence and molecular weight via Western blot and antibody staining.

Related Experiment Videos

  • Assessed viral titers and complement resistance of DAFF2A-modified retroviruses compared to wild-type.

    • Main Results:

    • The DAFF2A fusion protein conferred significant protection against human complement attack on amphotropic retroviruses.
    • DAFF2A-expressing retroviruses showed slightly reduced viral titers (1 x 10^5 CFU) compared to wild-type (5 x 10^5 CFU).
    • Blocking the DAF domain of DAFF2A restored complement sensitivity, confirming the fusion protein's role in protection.

    Conclusions:

    • The DAFF2A fusion protein effectively shields retroviruses from human complement, overcoming a major hurdle in gene therapy.
    • This novel approach offers a versatile tool for developing complement-resistant retroviral vectors for in vivo human gene therapy.
    • The method's applicability across cell types suggests broad potential for advancing gene therapy applications.